Tang Capital Management NVCR Position
Exited3-Fund ConvergenceTang Capital Management exited their position in NovoCure Ltd (NVCR) in Q4 2023, after holding the stock for 3 quarters.
The position was first reported in Q2 2023 and has been tracked across 3 quarterly 13F filings.
NVCR is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Pembrolizumab in 929 days (Oct 31, 2028), making the timing of Tang Capital's position particularly relevant.
Short interest stands at 11.7% of float with 3.9 days to cover, indicating significant bearish positioning against the stock.
About NovoCure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Full company profile →Short Interest
11.7%
3.9 days to cover
Tang Capital Management NVCR Position History
Frequently Asked Questions
Does Tang Capital Management own NVCR?
No. Tang Capital Management exited their position in NovoCure Ltd (NVCR) in Q4 2023. They previously held the stock for 3 quarters.
How many hedge funds own NVCR?
3 specialist biotech hedge funds currently hold NVCR, including Deep Track Capital, Deerfield Management, Rock Springs Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy NVCR?
Tang Capital Management's position in NVCR was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's NVCR position increasing or decreasing?
Tang Capital Management completely exited their NVCR position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
NVCRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →